
|Videos|July 31, 2020
AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PRIMAvera study: Central vision improvement with subretinal implant
2
Refractory dry eye care: How systemic conditions change the game
3
The year in optometry: 10 stories that defined eye care in 2025
4
Molecular insights and clinical experience: Extending anti-VEGF durability
5




